Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 7/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26161144 | 0.99 | PDK2 (0.39) | PDK2HSD17B1HSD17B2HPGDSFEN1 | |
| SCHEMBL20176483 | 0.95 | PDK2 (0.41) | PDK2HSD17B1HSD17B2HPGDSLDHA | |
| SCHEMBL26161147 | 0.95 | PDK2 (0.41) | PDK2HSD17B1HSD17B2HPGDSLDHA | |
| SCHEMBL26161311 | 0.94 | PDK2 (0.40) | PDK2HSD17B1HSD17B2FEN1ALOX5AP | |
| SCHEMBL26161330 | 0.94 | PDK2 (0.39) | PDK2HSD17B1HSD17B2HPGDSAXL | |
| SCHEMBL26161333 | 0.94 | PDK2 (0.39) | PDK2HSD17B1HSD17B2HPGDSAXL | |
| SCHEMBL26161263 | 0.94 | PDK2 (0.36) | PDK2HSD17B1HSD17B2HPGDSFEN1 | |
| SCHEMBL20176482 | 0.93 | HSD17B1 (0.36) | PDK2HSD17B1HSD17B2HPGDSFEN1 | |
| SCHEMBL26161145 | 0.92 | HSD17B1 (0.35) | PDK2HSD17B1HSD17B2HPGDSFEN1 | |
| SCHEMBL26161061 | 0.92 | PDK2 (0.40) | PDK2HSD17B1HSD17B2FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| WO-2018093231-A1 | ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING SAME | 주식회사 두산 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | OR10J3, ICMT, SLCO4C1 | PDK2 1916/4885HSD17B1 1993/4885HSD17B2 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.